Clinical Trial Update: Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating RP-G28 for lactose intolerance has been completed, assessing efficacy, durability, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lactose Intolerance

Drugs mentioned

• RP-G28

Snippet

Sponsor: Ritter Pharmaceuticals, Inc. | Conditions: Lactose Intolerance | Phase 3 | Status: COMPLETED